Related Experiment Video

Updated: Jun 4, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine

Melanie Mueller1, Jie Yuan, Concepcion Maldonado Adrian

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore 21224, USA.

Synapse (New York, N.Y.)
|March 2, 2011
PubMed

Insights

3,4-dihydroxymethamphetamine (HHMA) is not a precursor to toxic metabolites causing MDMA neurotoxicity. Blocking HHMA formation did not alter MDMA neurotoxicity, challenging previous hypotheses.

Area of Science:

  • Neuropharmacology
  • Toxicology
  • Metabolism Studies

Background:

  • 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity is a significant concern.
  • The metabolite 3,4-dihydroxymethamphetamine (HHMA) has been implicated as a precursor to toxic catechol-thioether metabolites responsible for MDMA neurotoxicity.

Purpose of the Study:

  • To investigate the role of HHMA in MDMA neurotoxicity.
  • To determine if blocking HHMA formation affects MDMA-induced neurotoxicity.

Main Methods:

  • Rats were administered MDMA with or without dextromethorphan (DXM) to inhibit HHMA formation.
  • Time-concentration profiles of MDMA and metabolites were measured.
  • Serotonin (5-HT) neuronal markers were assessed one week post-administration.

Main Results:

  • Dextromethorphan (DXM) effectively inhibited HHMA formation by over 70%.
  • DXM administration did not significantly alter core body temperature in MDMA-treated rats.
  • A significant reduction in HHMA formation did not impact the extent of MDMA neurotoxicity.

Conclusions:

  • The hypothesis that HHMA-derived catechol-thioether metabolites mediate MDMA neurotoxicity is not supported by these findings.
  • The mechanism of MDMA neurotoxicity likely involves pathways independent of HHMA formation.

More Related Videos

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...